Study Comparing Early Versus Delayed Use of Blood Thinners After Emergency Treatment for Stroke Caused by Atrial Fibrillation

What this Trial Is About

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants DOACs early versus delayed in patients who have an acute ischemic stroke related to atrial fibrillation and develop bleeding in the brain after emergency endovascular treatment. This multicenter, open-label, randomized controlled trial focuses on the best timing to begin DOAC therapy to help manage these patients and reduce risks of complications such as recurrent stroke or bleeding. Participants will be randomly assigned to one of two groups an early anticoagulation group starting DOACs within 4 weeks of stroke onset, and a delayed anticoagulation group starting DOACs between 4 and 8 weeks after stroke onset. The study compares these two approaches to determine which timing is safer and more effective for this condition. The treatments involve any direct oral anticoagulant drug, and the trial is conducted at multiple centers with an open-label design. During the study, participants will be closely monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Other assessments include measuring quality of life, hospital stay length, vascular events, and functional recovery using the modified Rankin scale. Researchers will collect data through imaging, clinical evaluations, and questionnaires. Follow-up is planned for 90 days after starting treatment to assess safety and overall health outcomes.

Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2